Kineta Trials - LARVOL Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

nesolicaftor (PTI-428) / Kineta

CHOICES, NCT06468527: Clinical Trial to Evaluate the Efficacy and Safety of Dirocaftor/Posenacaftor/Nesolicaftor in Adults With CF

Recruiting

Europe

Diponecaftor, Placebo

Kors van der Ent, European Union

Cystic Fibrosis

04/25

06/25

2017-003319-21: Study Assessing the Safety, Tolerability and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults with Cystic Fibrosis

Not yet recruiting

1/2

240

Europe, RoW

N-(5-hydroxy-2,4-bis(trimethylsilyl)phenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, Sodium (R)-8-methyl-2-(3-methylbenzofuran-2-yl)-5-(1-(tetrahydro-2H-pyran-4-yl)ethoxy)quinoline-4-ca, N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl)cyclobutyl)-3-phenylisoxazole-5-carboxamide, PTI-808, PTI-801, PTI-428, Capsule, hard

Proteostasis Therapeutics, Inc., Proteostasis Therapeutics, Inc.

Cystic fibrosis, Cystic fibrosis, Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

KVA12123 / Kineta

KEYNOTE-E67, NCT05708950: A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)

Recruiting

1/2

314

KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, Keytruda, KVA12123 - Dose Expansion, KVA12123 Plus Pembrolizumab - Dose Expansion

Kineta Inc., Merck Sharp & Dohme LLC

Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer

06/24

12/24

Undisclosed αCD27 mAb / Kineta

No trials found

Undisclosed ALS/FTLD therapeutic / Merck (MSD), Kineta

No trials found

YTX-9184 / Kineta

No trials found

αCD24 mAb / Kineta

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites